Skip to main content
Funded Studies

David Wustrow, PhD

Executive Director at XenoPort, Inc.

Location: Santa Clara, CA United States

Dr. Wustrow has 25 years of pharmaceutical research and development experience, primarily focused on treatments for disorders affecting the central nervous system. Since joining XenoPort in 2008, he has led efforts on a number of discovery programs and is currently executive director of scientific assessment. Prior to joining XenoPort, he was involved in several successful drug discovery and development efforts at Neurogen and Pfizer. Many of these led to successful IND filings, and programs he has led have achieved clinical proof of concept as treatments for insomnia, anxiety and pain. He is an author or inventor on over 100 publications, presentation abstracts and patents. He received his undergraduate degree from Penn State University and his PhD from the University of Rochester.


Associated Grants

  • A Novel Prodrug of Acamprosate for Treatment of L-DOPA-Induced Dyskinesias

    2010


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.